BioAtla, Inc.

NasdaqGM:BCAB Stock Report

Market Cap: US$33.5m

BioAtla Management

Management criteria checks 2/4

BioAtla's CEO is Jay Short, appointed in Mar 2007, has a tenure of 17.75 years. total yearly compensation is $3.30M, comprised of 21.6% salary and 78.4% bonuses, including company stock and options. directly owns 5.56% of the company’s shares, worth $1.86M. The average tenure of the management team and the board of directors is 4.7 years and 4.4 years respectively.

Key information

Jay Short

Chief executive officer

US$3.3m

Total compensation

CEO salary percentage21.6%
CEO tenure17.8yrs
CEO ownership5.6%
Management average tenure4.7yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

Oct 08

We're A Little Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Rate

Jul 16
We're A Little Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Rate

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

May 02

Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

Mar 14
Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

Is BioAtla (NASDAQ:BCAB) In A Good Position To Deliver On Growth Plans?

Nov 05
Is BioAtla (NASDAQ:BCAB) In A Good Position To Deliver On Growth Plans?

We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully

Jun 27
We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully

Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

Mar 24
Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

Sep 27
BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

BioAtla: Back From The Dead

Sep 23

BioAtla: Promising Signal In NSCLC, But Concerns Remain

Aug 23

BioAtla reports Q2 results

Aug 09

We're Keeping An Eye On BioAtla's (NASDAQ:BCAB) Cash Burn Rate

May 11
We're Keeping An Eye On BioAtla's (NASDAQ:BCAB) Cash Burn Rate

Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth

Jan 06
Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth

BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

Jul 24
BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

Are Insiders Buying BioAtla, Inc. (NASDAQ:BCAB) Stock?

Mar 16
Are Insiders Buying BioAtla, Inc. (NASDAQ:BCAB) Stock?

CEO Compensation Analysis

How has Jay Short's remuneration changed compared to BioAtla's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$82m

Jun 30 2024n/an/a

-US$105m

Mar 31 2024n/an/a

-US$119m

Dec 31 2023US$3mUS$713k

-US$123m

Sep 30 2023n/an/a

-US$124m

Jun 30 2023n/an/a

-US$117m

Mar 31 2023n/an/a

-US$110m

Dec 31 2022US$3mUS$686k

-US$106m

Sep 30 2022n/an/a

-US$102m

Jun 30 2022n/an/a

-US$99m

Mar 31 2022n/an/a

-US$101m

Dec 31 2021US$1mUS$660k

-US$95m

Sep 30 2021n/an/a

-US$79m

Jun 30 2021n/an/a

-US$68m

Mar 31 2021n/an/a

-US$44m

Dec 31 2020US$12mUS$636k

-US$27m

Sep 30 2020n/an/a

-US$22m

Dec 31 2019US$991kUS$610k

-US$29m

Compensation vs Market: Jay's total compensation ($USD3.30M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Jay's compensation has increased whilst the company is unprofitable.

CEO

Jay Short (66 yo)

17.8yrs

Tenure

US$3,301,346

Compensation

Dr. Jay M. Short, Ph D., serves as the Chairman and Chief Executive Officer of BioAtla, LLC. since March 2007.He is the Co-Founder of BioAtla, Inc. in March 2007. Dr. Short serves as an Advisor at SG Biof...

Leadership Team

NamePositionTenureCompensationOwnership
Jay Short
Co-Founder17.8yrsUS$3.30m5.56%
$ 1.9m
Richard Waldron
Senior VP & CFO11.1yrsUS$1.24m0.55%
$ 184.8k
Eric Sievers
Chief Medical Officer5.5yrsUS$1.32m0.17%
$ 57.0k
Christian Vasquez
Chief Accounting Officer9.1yrsUS$605.41k0.24%
$ 80.1k
Susie Melody
Senior Vice President of Human Resourcesno datano datano data
Cathy Chang
Senior Vice President of Research & Development3.9yrsno datano data
Gerhard Frey
Senior Vice President of Technology Development1.9yrsno datano data
Monica Sullivan
Senior Vice President of Intellectual Property & Contracts2.8yrsno datano data
Sheri Lydick
Chief Commercial Officer3.1yrsno datano data
Lisa Pelton
Accounting Managerno datano datano data

4.7yrs

Average Tenure

63yo

Average Age

Experienced Management: BCAB's management team is considered experienced (4.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jay Short
Co-Founder17.8yrsUS$3.30m5.56%
$ 1.9m
Lawrence Steinman
Independent Director4.4yrsUS$161.19k0.080%
$ 26.6k
Sylvia McBrinn
Independent Director3.5yrsUS$164.57k0.040%
$ 13.2k
Mary Gray
Independent Director4yrsUS$180.44k0.077%
$ 25.9k
James Allison
Advisor7.1yrsno datano data
Edward Williams
Independent Director3yrsUS$168.94k0.042%
$ 14.0k
Padmanee Sharma
Advisor7.1yrsno datano data
Scott Smith
Director4.4yrsUS$1.77m0.55%
$ 184.7k
Lawrence Fong
Scientific Advisor6.4yrsno datano data
Susan Moran
Independent Director4yrsUS$158.19k0.025%
$ 8.5k

4.4yrs

Average Tenure

68yo

Average Age

Experienced Board: BCAB's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 18:23
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioAtla, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas ShraderBTIG
Justin ZelinBTIG
Tiago FauthCredit Suisse